ArticleLeukemia2016
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.
Abstract readLetter
In one paragraph
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Nano-engineered phytochemicals in cancer therapy: mechanistic insights into apoptosis, ferroptosis, tumor microenvironment modulation and drug resistance reversal.Apoptosis : an international journal on programmed cell death · 2026Review
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
- Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems.Journal of translational medicine · 2026Review
- Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential.Biomedicines · 2026Review
- Parthenolide alleviates doxorubicin-induced cardiotoxicity via regulation ofJournal of traditional and complementary medicine · 2025Article
- Targeting myeloid cells for hematological malignancies: the present and future.Biomarker research · 2025Review
- Parthenolide: pioneering new frontiers in hematological malignancies.Frontiers in pharmacology · 2025Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.European journal of medical research · 2024Review
- Nanoparticle-encapsulated retinoic acid for the modulation of bone marrow hematopoietic stem cell niche.Bioactive materials · 2024Article
- Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia.Journal of nanobiotechnology · 2023Review
- Parthenolide Phytosomes Attenuated Gentamicin-Induced Nephrotoxicity in Rats via Activation of Sirt-1, Nrf2, OH-1, and NQO1 Axis.Molecules (Basel, Switzerland) · 2023Article
- Bone marrow-targetable Green Tea Catechin-Based Micellar Nanocomplex for synergistic therapy of Acute myeloid leukemia.Journal of nanobiotechnology · 2022Article
- Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases.Frontiers in genome editing · 2022Review
- The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.Drug design, development and therapy · 2022Review
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD).European journal of medicinal chemistry · 2021Article
- Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome.Cancers · 2021Article
- The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors.Beilstein journal of nanotechnology · 2021Review
- Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.Nature communications · 2020Review
- Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin's Lymphoma Cell Lines.Materials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
H ZongDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
S SenDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
G ZhangDepartment of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA.
C MuDepartment of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA.
Z F AlbayatiUniversity of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, AR, USA.
D G GorensteinInstitute of Molecular Medicine, The University of Texas-Houston Medical School, Houston, TX, USA.
X LiuDepartment of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA.
M FerrariDepartment of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA.
P A CrooksUniversity of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, AR, USA.
G J RobozDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
H ShenDepartment of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA.
M L GuzmanDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Funding
The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1MPHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AMLR01CA102031 · NCI · OHIO STATE UNIVERSITY · PI GUZMAN, MONICA L, MARCUCCI, GUIDO · 2004 to 2017
$3.8MSelection of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem CellDP2OD007399 · OD · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUZMAN, MONICA L · 2010 to 2010
$2.5MA role for elevated autophagy in survival and chemoresistance of leukemia stem ceR21CA158728 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUZMAN, MONICA L · 2012 to 2013
$393kNCI NIH HHS R01 CA102031NCI NIH HHS R21 CA158728NIGMS NIH HHS P20 GM109005NIH HHS DP2 OD007399
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteAnimalsAntineoplastic AgentsBone MarrowCell Line, TumorDrug Delivery SystemsHumansMiceMice, Inbred NODMice, SCIDNanoparticlesNeoplastic Stem CellsSesquiterpenesStem Cell NicheXenograft Model Antitumor AssaysAntineoplastic AgentsparthenolideSesquiterpenes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.